Overview of surfactant replacement trials.
Overview of surfactant replacement trials.
复制标题
DOI：
10.1038/sj.jp.7211320
复制
发表时间：
2005-05-01
期刊：
影响因子：
--
通讯作者：
Soll, Roger F
中科院分区：
文献类型：
--
作者：
Suresh, Gautham K;Soll, Roger F
临床试验评估了表面活性剂治疗的总体疗效，以及不同表面活性剂制剂的相对疗效、最佳给药时机和最佳剂量。表面活性剂治疗可显着改善有呼吸窘迫综合征 (RDS) 风险或患有呼吸窘迫综合征 (RDS) 的婴儿的临床症状。将合成或动物源性表面活性剂制剂与安慰剂或无治疗效果进行比较的临床试验表明，表面活性剂治疗可快速改善氧合、减少呼吸机支持、降低气胸风险和死亡率。早期治疗、对发生 RDS 高风险婴儿的预防性治疗以及选择性再治疗也可以改善临床结果。目前可用的动物源表面活性剂优于不含蛋白质的合成表面活性剂。正在进行的评估将确定是否注意到动物源性产品的重要差异。未来的试验将评估第三代表面活性剂产品，并进一步完善表面活性剂的最佳使用构成。
Clinical trials have evaluated the overall efficacy of surfactant therapy, as well as the relative efficacy of different surfactant preparations, the optimal timing of administration and the optimal dosage. Surfactant therapy leads to significant clinical improvement in infants at risk for, or having, respiratory distress syndrome (RDS). Clinical trials that compared the effects of synthetic or animal-derived surfactant preparations to placebo or no therapy demonstrate that surfactant therapy lead to rapid improvement in oxygenation, decreased ventilator support, decreased risk of pneumothorax, and mortality. Earlier treatment, prophylactic treatment of infants at high risk of developing RDS, and selective re-treatment leads to improved clinical outcome as well. Currently available animal-derived surfactants are superior to non-protein-containing synthetic surfactants. Ongoing evaluation will determine if important differences in animal-derived products are noted. Future trials will evaluate third-generation surfactant products and further refine what constitutes optimal use of surfactant.